Literature DB >> 3031174

Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus.

B Meignier, T M Jourdier, B Norrild, L Pereira, B Roizman.   

Abstract

Artificial mixtures of the glycoproteins B, C, D, and E of herpes simplex virus 1 and 2 (HSV-1 and HSV-2), purified individually from infected Vero cell lysates by immunoaffinity to monoclonal antibodies, were bound to an aluminum hydroxide gel and were used to immunize mice, guinea pigs, and owl monkeys (Aotus trivirgatus) once or twice (mice and guinea pigs) to as many as four times (owl monkeys). In all animals tested, low levels of neutralizing antibodies were detected only after two or more immunizations. Lymphocyte transformation tests in owl monkeys suggested low or borderline levels of cellular immunity. The survival of immunized mice after intracerebral challenge was inversely related to the challenge dose. Immunized guinea pigs challenged by intravaginal inoculation showed reduced morbidity at the site of inoculation and were protected from CNS disease. Both immunized and nonimmunized monkeys were highly susceptible and could not be differentiated with respect to morbidity or mortality when challenged with 1,000 pfu of HSV-2 by the intravaginal route.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3031174     DOI: 10.1093/infdis/155.5.921

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

Review 1.  Herpes simplex viruses: is a vaccine tenable?

Authors:  Richard J Whitley; Bernard Roizman
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

2.  Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.

Authors:  Sita Awasthi; Elizabeth E Zumbrun; Huaxin Si; Fushan Wang; Carolyn E Shaw; Michael Cai; John M Lubinski; Shana M Barrett; John W Balliet; Jessica A Flynn; Danilo R Casimiro; Janine T Bryan; Harvey M Friedman
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

3.  Acute and latent infection of mice immunised with HSV-1 ISCOM vaccine.

Authors:  M Erturk; T J Hill; C Shimeld; R Jennings
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

4.  Analogues of peptide 9-21 of glycoprotein D of herpes simplex virus and their binding to group VII monoclonal antibodies.

Authors:  S Welling-Wester; M Feijlbrief; D G Koedijk; J W Drijfhout; W J Weijer; A J Scheffer; G W Welling
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

5.  Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.

Authors:  Yo Hoshino; Sarat K Dalai; Kening Wang; Lesley Pesnicak; Tsz Y Lau; David M Knipe; Jeffrey I Cohen; Stephen E Straus
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Glycoprotein B of herpes simplex virus type 1 oligomerizes through the intermolecular interaction of a 28-amino-acid domain.

Authors:  S Laquerre; S Person; J C Glorioso
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

7.  Latent HSV-1 infection in mice immunized with a zwitterionic detergent-extracted HSV-1 antigen preparation.

Authors:  A al-Ghamdi; R Jennings; H Bentley; C W Potter
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

8.  Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs.

Authors:  Yo Hoshino; Lesley Pesnicak; Kennichi C Dowdell; Juan Lacayo; Timothy Dudek; David M Knipe; Stephen E Straus; Jeffrey I Cohen
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

Review 9.  Herpes simplex virus type 2 vaccines: new ground for optimism?

Authors:  L Aurelian
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

10.  Zwitterionic detergent solubilisation of HSV-1 surface antigens.

Authors:  R Jennings; T Quasim; R M Sharrard; D Hockley; C W Potter
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.